CLNN - Clene Inc
IEX Last Trade
5.23
-0.150 -2.868%
Share volume: 23,471
Last Updated: Fri 30 Aug 2024 09:59:36 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$5.38
-0.15
-2.79%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-2.41%
1 Month
16.85%
3 Months
-22.77%
6 Months
-39.29%
1 Year
-65.37%
2 Year
-91.19%
Key data
Stock price
$5.23
DAY RANGE
N/A - N/A
52 WEEK RANGE
$3.82 - $15.57
52 WEEK CHANGE
-$0.64
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO:
Region: US
Website: clenenanomedicine.com
Employees: 62
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: clenenanomedicine.com
Employees: 62
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
clene has a new vision for a pharmaceutical future using therapeutic elements in clean, new nanoforms. our patented clean-surface nanosuspension™ (csn) technology produces clean-surface nanocrystals at commercially viable rates. by coupling high-purity metallic donor materials with high-purity water, csn unlocks the potential of therapeutic nanoparticles and represents a clean break from the standard paradigm of small-molecule drugs and large-molecule biologics.
Recent news